SCHEMBL19833830

SCHEMBL19833830

O=C1COc2cc(F)c(C(=O)N3CC(COc4ccc(Cl)cc4)C3)cc2N1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MGLL Q99685 5/20 0.48
▸ HTR1A P08908 5/20 0.39
▸ DRD4 P21917 2/20 0.39
▸ DRD2 P14416 2/20 0.39
▸ DRD3 P35462 2/20 0.39
▸ CHRM5 P08912 1/20 0.39
▸ ADRA2A P08913 1/20 0.39
▸ ADRA2B P18089 1/20 0.39
▸ HTR2A P28223 1/20 0.39
▸ ADRA1B P35368 1/20 0.39
▸ TMEM97 Q5BJF2 1/20 0.39
▸ SIGMAR1 Q99720 1/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ MAPT P10636 2/20 0.39
▸ RXFP1 Q9HBX9 1/20 0.39
▸ TP53 P04637 2/20 0.39
▸ HTR1D P28221 3/20 0.38
▸ HTR1B P28222 3/20 0.38
▸ ADRB1 P08588 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19834134 0.93 MGLL (0.49) MGLLHTR1ADRD2DRD3HTR2A
SCHEMBL19833724 0.93 MGLL (0.47) MGLLHTR1ADRD2DRD3ALDH1A1
SCHEMBL19833878 0.92 MGLL (0.45) MGLLHTR1AMAPTRXFP1HTR1D
SCHEMBL19834073 0.91 MGLL (0.49) MGLLHTR1ADRD2HTR2AALDH1A1
SCHEMBL19834121 0.91 MGLL (0.49) MGLLHTR1ADRD2HTR2AALDH1A1
SCHEMBL19834049 0.91 MGLL (0.44) MGLLHTR1AMAPTRXFP1HTR1D
SCHEMBL19834071 0.91 MGLL (0.44) MGLLHTR1ADRD4DRD2DRD3
SCHEMBL19834127 0.91 MGLL (0.46) MGLLHTR1AKDM4EALDH1A1TP53
SCHEMBL19833887 0.90 MGLL (0.46) MGLLHTR1ADRD2DRD3MAPT
SCHEMBL19833838 0.90 MGLL (0.44) MGLLHTR1AALDH1A1MAPTRXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3279191-B1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2020-09-02 — — EP disclosed
EP-3279191-B1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2020-09-02 — — EP disclosed
US-10106556-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2018-10-23 — — US disclosed
US-20180079756-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2018-03-22 — — US disclosed
US-20180079756-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2018-03-22 — — US disclosed
EP-3279191-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2018-02-07 — — EP disclosed
EP-3279191-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2018-02-07 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180079756-A1 HETEROCYCLIC COMPOUND MAG, ACHE, HTT MGLL 129/4885HTR1A 381/4885DRD4 1377/4885
US-10106556-B2 Heterocyclic compound MAG, ACHE, HTT MGLL 129/4885HTR1A 381/4885DRD4 1377/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback